We rank companies based on fund manager, research analyst and news sentiment
HOTH stock icon

Hoth Therapeutics
HOTH

$1.15
1.3%
 

About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Employees: 3

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

8% more funds holding

Funds holding: 12 [Q3] → 13 (+1) [Q4]

1.1% less ownership

Funds ownership: 2.92% [Q3] → 1.82% (-1.1%) [Q4]

22% less capital invested

Capital invested by funds: $146K [Q3] → $113K (-$32.2K) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$4
248%
upside
Avg. target
$5
335%
upside
High target
$7
509%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
248%upside
$4
Buy
Reiterated
5 Apr 2024
EF Hutton
Tim Moore
509%upside
$7
Buy
Maintained
2 Apr 2024
HC Wainwright & Co.
Raghuram Selvaraju
248%upside
$4
Buy
Initiated
5 Feb 2024

Financial journalist opinion